ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SNGX / news
UPC (33) TCRT (36) CURX (37) MTVA (31) ⌘ Pro Terminal →

Why SNGX Stock advanced +1.49% Today — RQD Quant Desk Flash

$0.36 +1.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.36

Soligenix Inc. (SNGX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $7.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Soligenix Inc. (NASDAQ: SNGX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.36 (+1.49% 1D, market cap $7.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SNGX ranks #431 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNGX compare to UPC and TCRT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNGX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, UPC (Universe Pharmaceuticals Inc. (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC —, cap $7.5M) and TCRT (Alaunos Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M). Among the 5-stock peer group, SNGX leads on earnings multiple (N/A) while SNGX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNGX?
▼

Per SNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000812796), Soligenix Inc. generated $33.2M in revenue (+27685.1% YoY), -$11.1M in net income, and -$10.3M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.36 (+0.08%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (11)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.3% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE SNGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY SNGX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$0.33+6.1% Next Q
Q2 (-2Q)
37
Grade E$0.35+2.9% Next Q
Q3 (-1Q)
39
Grade E$0.36+0% Next Q
Current
42
Grade D-$0.36-7% Hist 90D α
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNGX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.37) and Max Pain ($0.38) forces dealer call-delta covering toward $1.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SNGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why SNGX Stock advanced +1.49% Today — RQD Quant Desk Flash

Soligenix Inc. (SNGX) advanced +1.49% to $0.36, trading at 6% of its 52-week range ($0.28 – $1.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 6% of its 52-week range ($0.28 – $1.7) with RSI-14 at 49.3 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.36 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SNGX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNGX)

  • ✓Walkthrough of SNGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.86%⚡ TESTING RESISTANCE
2026-11-03O $0.37H $0.37L $0.36C $0.36VOL 69.7K
RES: $0.38SUP: $0.30SMA50: $0.37SMA200: $0.67
$1.72$1.33$0.94$0.55$0.16RES $0.38SUP $0.30$0.362026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNGX Butterfly Map → + Track SNGX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +27685.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SNGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNGX)

Health Care Rank #431 of 1015 ⚔️ UPC vs SNGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNGX vs. UPC, TCRT, CURX, MTVA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Soligenix Inc. (SNGX) ranks #431 by composite RQD confidence (42/100, grade D-) and #912 by equity capitalization ($7.7M). Within this direct 5-issuer industry benchmark cohort, SNGX leads on earnings valuation at N/A trailing P/E, while SNGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SNGX currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SNGX ACTIVE
Soligenix Inc.
D- 42/100 — — -35.0% +1.49% $7.7M Benchmark Subject
UPC
Universe Pharmaceuticals Inc. (Class A)
E 33/100 — 35.3% — -1.34% $7.5M /upc-vs-sngx →
TCRT
Alaunos Therapeutics Inc.
D- 36/100 — — -35.0% -10.26% $8.1M /tcrt-vs-sngx →
CURX
Curanex Pharmaceuticals Inc
D- 37/100 — — -35.0% +13.37% $8.1M /curx-vs-sngx →
MTVA
MetaVia Inc.
E 31/100 — — -35.0% +4.46% $7.4M /mtva-vs-sngx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000812796 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Soligenix Inc. (SNGX) reported GAAP revenue of $33.2M (+27685.1% vs. FY2024 revenue of $119.4K , and +3851.5% cumulative change since FY2023) , GAAP net income of -$11.1M, operating cash flow of -$10.3M, and free cash flow of -$10.3M (-22.2% YoY). On the balance sheet, SNGX closed FY2025 with $9.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $33.2M -$11.1M -$10.3M -$10.3M $9.2M —
FY2024 (FY) 2024-12-31 $119.4K -$8.3M -$8.4M -$8.4M $9.0M —
FY2023 (FY) 2023-12-31 $839.4K -$6.1M -$8.6M -$8.6M — —

3. SNGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Soligenix Inc. (NASDAQ: SNGX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.36 (+1.49% 1D, market cap $7.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SNGX ranks #431 in composite RQD confidence.

How does SNGX compare to UPC and TCRT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNGX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, UPC (Universe Pharmaceuticals Inc. (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC —, cap $7.5M) and TCRT (Alaunos Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M). Among the 5-stock peer group, SNGX leads on earnings multiple (N/A) while SNGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNGX?

Per SNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000812796), Soligenix Inc. generated $33.2M in revenue (+27685.1% YoY), -$11.1M in net income, and -$10.3M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNGX trading relative to its 50-day, 200-day, and 52-week technical levels?

SNGX last traded at $0.36 (+1.49% on volume of 137,411 shares), positioning the stock -2.70% below its 50-day simple moving average ($0.37) and -46.27% below its 200-day simple moving average ($0.67). Across its 52-week range of $0.28 to $1.70, SNGX sits at the 5.6% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.40).

Direct Sub-Reports: SNGX RQD Cockpit SNGX 12M Forecast SNGX Earnings & Move SNGX Dividends & DRIP SNGX Insiders & 13F SNGX Whale Options SNGX Profit Sankey SNGX News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SNGX — Soligenix Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Soligenix Inc. (SNGX) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.36 (+1.49% 1D, market capitalization $7.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Soligenix Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Its reported revenue is — for FY 2025, $0.1M for FY 2024, and $0.8M for FY 2023, which indicates declining revenue over the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Soligenix Inc. (SNGX) reported $33.2M in annual revenue (up from $119.4K in FY2024, +27685.1% YoY) and -$11.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($839.4K revenue, -$6.1M net income) through FY2025, SNGX scaled operating cash flow to -$10.3M and free cash flow to -$10.3M, backed by $9.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.28 – $1.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream dependencies, no sector correlations, and no proprietary signals recorded.

  • Key Question #1: Can SNGX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $33.2M and free cash flow of -$10.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SNGX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SNGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Soligenix Inc. (SNGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNGX Bull vs. Bear Conversation Board — What's Your Call at $0.36?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNGX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SNGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $0.44 (+22.2%)
📌 Pinned Debate

Institutional accumulation and options positioning score 11 / 20 in the RQD rating, the highest of the five pillars, indicating some fl

The street is overcomplicating Soligenix Inc. (SNGX). Institutional accumulation and options positioning score 11 / 20 in the RQD rating, the highest of the five pillars, indicating some flow support.. With an RQD score of 42/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.39.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.29 (-19.4%)
Spot @ $0.36

ROIC of -35% and FCF yield of 0% with reported FY 2025 free cash flow of -$10.3M point to a business not currently generating cash.

I respect the product at Soligenix Inc., but the stock at $0.36 is a different story. ROIC of -35% and FCF yield of 0% with reported FY 2025 free cash flow of -$10.3M point to a business not currently generating cash.. FCF yield is 0.0% and RQD sits at 42/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE